EyePoint Pharmaceuticals, Inc. (EYPT) Downgraded to Neutral by HC Wainwright & Co.

Market Context

EyePoint Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $5.23 with a market capitalization of $1.1B. The stock has declined 55.1% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow HC Wainwright & Co.'s research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for EyePoint Pharmaceuticals, Inc.

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 18, 2026	RBC Capital	Sector Perform	N/A
Aug 18, 2026	Chardan Capital	Neutral	N/A
Aug 18, 2026	HC Wainwright & Co.	Neutral	N/A
Aug 17, 2026	Jefferies	Buy	N/A
Aug 17, 2026	JP Morgan	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View EYPT Stock Page